Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C25H37NO4 · C11H8O3
Número CAS:
Peso molecular:
603.75
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Salmeterol xinafoate, ≥98% (HPLC), solid
Quality Level
assay
≥98% (HPLC)
form
solid
color
white
solubility
H2O: slightly soluble, ethanol: slightly soluble, methanol: freely soluble
originator
GlaxoSmithKline
SMILES string
OC(=O)c1ccc2ccccc2c1O.OCc3cc(ccc3O)C(O)CNCCCCCCOCCCCc4ccccc4
InChI
1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
InChI key
XTZNCVSCVHTPAI-UHFFFAOYSA-N
Gene Information
human ... ADRB2(154)
Application
Salmeterol xinafoate was used as conjugate with human serum albumin to study the immune responses in rabbits.7
Biochem/physiol Actions
β2-adrenoceptor agonist.
Salmeterol xinafoate is a β2 adrenoceptor agonist with longer lasting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles, stabilizes mast cells and regulates the release of histamine. Salmetrol is particularly effective in treatment of mild asthma, chronic obstructive pulmonary disorder.5,6
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Claus Vogelmeier et al.
Respiratory medicine, 107(1), 75-83 (2012-10-30)
The objective of this study was to investigate the effect of tiotropium compared with salmeterol on exacerbations in patients with moderate (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) chronic obstructive pulmonary disease (COPD) and those naïve to
Marc Decramer et al.
Respiratory medicine, 107(2), 223-232 (2012-12-12)
Indacaterol is a once-daily, long-acting β(2)-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are
Finney, P.A., et al.
British Journal of Pharmacology, 132, 1267-1270 (2001)